Organon Entered into a Research Collaboration and Exclusive License Agreement with Cirqle Biomedical for Non-hormonal Contraceptive Therapy

Shots:

Cirqle to receive a $10M up front & is eligible to receive ~$360M in milestones along with royalties on net sales
Organon to get an exclusive right globally to develop and commercialize the product while Cirqle will be responsible for conducting the preclinical studies based on the research collaboration
The collaboration continues to expand the portfolio in women’s health to address patient unmet needs. The collaboration will use Organon’s deep expertise in women’s and reproductive health to bring new options for women who use contraception everywhere

Ref: Bussinesswire | Image: Organon